2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4279 Younger sickle cell disease patients have excellent survival with preserved organ function following matched related donor hematopoietic cell transplantation

Caroline Snyder, MPH, Ann Haight, MD2, Suhag Parikh, MD3, Elizabeth Stenger, MD MSc4
1 Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, Emory University, Atlanta, United States
2 Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, Emory University, Atlanta, United States
3 Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, Emory University, Atlanta, United States
4 Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, Emory University, Atlanta, United States

Sickle cell disease (SCD) is an inherited hemoglobinopathy with progressive multiorgan damage and reduced survival. Allogeneic hematopoietic cell transplantation (HCT) is the only established cure, and younger age at HCT is associated with better outcomes and may mitigate SCD-related injury. We evaluated the impact of age at HCT on outcomes and long-term organ function in pediatric SCD.

This single-center, retrospective study included SCD patients (pts) post allogeneic HCT from 1993–2025 with ≥1 year (yr) follow-up. Data were obtained from electronic health record and institutional REDCap database. Age at HCT was categorized as ≤11 vs ≥12 yrs. Transplant characteristics, HCT complications, and organ function were abstracted. Primary outcomes were overall, rejection-free, and severe GVHD/rejection-free survival (OS, RFS, GRFS), analyzed using Kaplan–Meier methods, log-rank tests, and Cox proportional hazards models adjusted for key covariates. Cumulative incidence (CI) of graft failure (GF)/2nd HCT, severe GVHD, and death to 2 yrs were compared by Gray’s test. Estimated glomerular filtration rate (eGFR) was calculated using updated Schwartz formula. Organ function was compared pre- and post-HCT and by age using paired/two-sample t-tests and χ²/Fisher’s exact tests. Logistic regression was used to evaluate predictors of severe GVHD or GF/2nd HCT.

Across 125 pts, 78% were ≤11 yrs at HCT and most received bone marrow (96%) with myeloablative conditioning (95%). Older pts were more likely to have severe disease (85% vs 59%, p=0.015), be male (75% vs 45%, p=0.006), and to have an older donor (17 vs 8 yrs, p<0.001); younger pts had longer follow up (7.7 vs 4.7 yrs; p<0.001). Transplant outcomes were excellent and did not differ by age. One young pt underwent 2nd MRD (same donor) HCT ~1.5 yrs post 1st due to poor graft function. Any GVHD occurred in 24% of young vs 32% of older pts (p=0.40), with acute in 19% vs 11% (p=0.40) and chronic in 11% vs 25% (p=0.12). Severe GVHD was rare, with grade III-IV acute in 2.1% vs 3.6% (p=0.50) and severe/extensive chronic in 4.1% vs 11% (p=0.20). There was no difference in time to off immunosuppression by age (304 vs 365 days, p=0.41). All deaths were in younger pts (N=3) at 0.3, 0.9, and 9.2 yrs post-HCT, due to GVHD, septic shock, and heart failure.

CI of GF, severe GVHD, and death were low and did not significantly differ by age. While older age in yrs and CMV D/R (high vs low risk) was associated with higher odds of severe GVHD or GF (age OR 1.12 [0.96–1.30], p=0.148; CMV OR 2.95 [0.65-20.61), p=0.197), neither was predictive in multivariable modeling. Year of HCT, sex, disease severity, conditioning intensity, ABO matching, and graft source were not significantly associated with severe GVHD or GF. At 2 yrs, no significant difference was seen in survival by age at HCT, with OS 98% vs 100% (p=0.446), RFS 99% vs 100% (p=0.586), and GRFS 95% vs 89% (p=0.289) in younger and older pts.

Organ function showed modest decline pre- to post-HCT, with younger pts maintaining higher values. At mean of 4.9 yrs, mean ejection fraction (EF; N=114; 67.7→65.7%, p=0.005) and shortening fraction (SF; N=110; 37.1→36.1%, p=0.043) significantly decreased, but did not differ by age. Longitudinally, younger pts maintained but older pts had significant decline at 2 yrs in EF (62.0→67.0%, p=0.009) and SF (33.5→36.7%, p=0.017). At mean of 5.6 yrs, mean FEV1 and FVC (N=86) did not significantly differ overall or by age. Longitudinally, pts ≤11 yrs maintained FEV1 and FVC, whereas those ≥12 yrs had significantly lower FEV1 (79.7% vs 99.2%, p=0.002) and FVC (83.3% vs 98.3%, p=0.003) at yr 5. At mean of 6 yrs (N=89), mean eGFR declined 224.1→154.7 mL/min/1.73 m²; while no difference was seen by age in Δ, younger pts had significantly higher mean baseline (232.0 vs 195.1, p=0.018) and post-HCT (158.5 vs 141.0, p=0.033) values. While no significant categorical differences were seen by age (p=0.05), older pts with pre-HCT hyperfiltration were more likely to have normal eGFR post-HCT (68% vs 37%, p=0.01).

Allogeneic HCT achieved excellent survival with low GF, severe GVHD, and mortality across age groups. The study was underpowered to detect small age-related differences, however, trends suggested cardiac and pulmonary decline in older patients and better long-term organ function in younger patients. Future work will incorporate neurologic and endocrine function to further characterize organ injury by age.

Elizabeth Stenger, MD MSc: Vertex pharmaceuticals - Honoraria